➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Moodys
Medtronic
Johnson and Johnson
Dow
Merck

Last Updated: June 5, 2020

DrugPatentWatch Database Preview

Mylan Institutional Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for MYLAN INSTITUTIONAL, and what generic and branded alternatives to MYLAN INSTITUTIONAL drugs are available?

MYLAN INSTITUTIONAL has sixty approved drugs.



Drugs and US Patents for Mylan Institutional

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Institutional DURACLON clonidine hydrochloride INJECTABLE;INJECTION 020615-002 Apr 27, 1999 AP RX Yes Yes   Start Trial   Start Trial
Mylan Institutional DIPHENHYDRAMINE HYDROCHLORIDE diphenhydramine hydrochloride INJECTABLE;INJECTION 040498-001 Jul 12, 2005 AP RX No No   Start Trial   Start Trial
Mylan Institutional ENLON-PLUS atropine sulfate; edrophonium chloride INJECTABLE;INJECTION 019677-001 Nov 6, 1991 DISCN No No   Start Trial   Start Trial
Mylan Institutional ROCURONIUM BROMIDE rocuronium bromide INJECTABLE;INJECTION 079199-002 Nov 26, 2008 AP RX No No   Start Trial   Start Trial
Mylan Institutional FOMEPIZOLE fomepizole INJECTABLE;INJECTION 078639-001 Mar 3, 2008 AP RX No Yes   Start Trial   Start Trial
Mylan Institutional MESNA mesna INJECTABLE;INTRAVENOUS 076488-001 Mar 8, 2012 DISCN No No   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Mylan Institutional

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-002 Jul 12, 1996 5,466,700*PED   Start Trial
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-002 Jul 12, 1996 5,019,583*PED   Start Trial
Mylan Institutional SULFAMYLON mafenide acetate CREAM;TOPICAL 016763-001 Approved Prior to Jan 1, 1982 3,497,599   Start Trial
Mylan Institutional ENLON-PLUS atropine sulfate; edrophonium chloride INJECTABLE;INJECTION 019678-001 Nov 6, 1991 4,952,586   Start Trial
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-001 Jul 12, 1996 5,866,591*PED   Start Trial
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-001 Jul 12, 1996 5,466,700*PED   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for MYLAN INSTITUTIONAL drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 100 mg/mL, 2.5 mL vials ➤ Subscribe 2007-09-24
➤ Subscribe for Injection 1 mg/vial, 2 mg/vial and 5 mg/vial ➤ Subscribe 2013-12-27
➤ Subscribe Injection 1 mg/mL, 50 mL vials ➤ Subscribe 2011-12-16
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
AstraZeneca
McKinsey
Harvard Business School
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.